“We will also pursue interventions to prevent rebound of viremia after interruption of antiretroviral therapy (ART), and we will leverage a broad portfolio of tools from both academic and industry partners, and apply new discoveries, demonstrating proof-of-concept for clinical initiatives.” “We will continue to pursue our central unifying hypothesis that reversing HIV latency will ultimately lead to eradication of persistent HIV infection,” Margolis said. CARE will now expand its expertise and work toward a better understanding of persistent HIV infection, the discovery of novel approaches to disrupt HIV latency, methods to clear the HIV reservoir, and identification of strategies to control viral rebound. Since its inception in 2011, the Martin Delaney Collaboratory program has made important advances towards a cure for HIV. David Margolis, professor of medicine at the UNC School of Medicine, director of the UNC HIV Cure Center. The Collaboratory of AIDS Researchers for Eradication, or CARE, which will receive $5.2 million for each of the next five years, was one of the two original collaboratory programs funded since the beginning, along with UC San Francisco. Additionally, one of the new grants is focused specifically on HIV cure research in infants and children. The new awards for the Martin Delaney Collaboratories for HIV Cure Research program, initiated in 2011, further expand the initiative’s 2016 renewal from six institutions to 10, and represent a funding increase of approximately 75%. The National Institutes of Health has awarded approximately $53 million in annual funding over the next five years to 10 research organizations in a continued effort to find a cure for HIV.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |